Lucid Diagnostics Stock Current Valuation
| LUCD Stock | USD 0.77 0.02 2.37% |
Valuation analysis of Lucid Diagnostics helps investors to measure Lucid Diagnostics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value Over EBITDA is expected to grow to -1.05. The current year's Enterprise Value Multiple is expected to grow to -1.05. Fundamental drivers impacting Lucid Diagnostics' valuation include:
Price Book 2.159 | Enterprise Value 101.1 M | Enterprise Value Ebitda (0.67) | Price Sales 11.1262 | Enterprise Value Revenue 24.1355 |
Undervalued
Today
Please note that Lucid Diagnostics' price fluctuation is very risky at this time. Calculation of the real value of Lucid Diagnostics is based on 3 months time horizon. Increasing Lucid Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Lucid stock is determined by what a typical buyer is willing to pay for full or partial control of Lucid Diagnostics. Since Lucid Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lucid Stock. However, Lucid Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.77 | Real 1.66 | Target 4.36 | Hype 0.79 |
The real value of Lucid Stock, also known as its intrinsic value, is the underlying worth of Lucid Diagnostics Company, which is reflected in its stock price. It is based on Lucid Diagnostics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Lucid Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Lucid Diagnostics helps investors to forecast how Lucid stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lucid Diagnostics more accurately as focusing exclusively on Lucid Diagnostics' fundamentals will not take into account other important factors: Lucid Diagnostics Company Current Valuation Analysis
Lucid Diagnostics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Lucid Diagnostics Current Valuation | 101.1 M |
Most of Lucid Diagnostics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lucid Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lucid Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Lucid Diagnostics is extremely important. It helps to project a fair market value of Lucid Stock properly, considering its historical fundamentals such as Current Valuation. Since Lucid Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lucid Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lucid Diagnostics' interrelated accounts and indicators.
Click cells to compare fundamentals
Lucid Current Valuation Historical Pattern
Today, most investors in Lucid Diagnostics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lucid Diagnostics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Lucid Diagnostics current valuation as a starting point in their analysis.
Lucid Diagnostics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Lucid Diagnostics has a Current Valuation of 101.1 M. This is 99.3% lower than that of the Health Care Equipment & Supplies sector and 99.19% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.39% higher than that of the company.
Lucid Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lucid Diagnostics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lucid Diagnostics could also be used in its relative valuation, which is a method of valuing Lucid Diagnostics by comparing valuation metrics of similar companies.Lucid Diagnostics is currently under evaluation in current valuation category among its peers.
Lucid Fundamentals
| Return On Equity | -10.08 | ||||
| Return On Asset | -1.01 | ||||
| Operating Margin | (9.98) % | ||||
| Current Valuation | 101.1 M | ||||
| Shares Outstanding | 59.34 M | ||||
| Shares Owned By Insiders | 60.83 % | ||||
| Shares Owned By Institutions | 4.18 % | ||||
| Number Of Shares Shorted | 421.84 K | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 11.13 X | ||||
| Revenue | 2.43 M | ||||
| Gross Profit | (3.24 M) | ||||
| EBITDA | (49.75 M) | ||||
| Net Income | (52.67 M) | ||||
| Cash And Equivalents | 34.46 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 15.26 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.55 X | ||||
| Book Value Per Share | (0.96) X | ||||
| Cash Flow From Operations | (32.82 M) | ||||
| Short Ratio | 0.80 X | ||||
| Earnings Per Share | (1.12) X | ||||
| Target Price | 3.5 | ||||
| Number Of Employees | 70 | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 46.61 M | ||||
| Total Asset | 27.27 M | ||||
| Retained Earnings | (150.74 M) | ||||
| Working Capital | (7.31 M) | ||||
| Net Asset | 27.27 M |
About Lucid Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lucid Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lucid Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lucid Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out Lucid Diagnostics Piotroski F Score and Lucid Diagnostics Altman Z Score analysis. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.09 | Quarterly Revenue Growth 0.497 | Return On Assets (1.01) | Return On Equity (10.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.